{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["63(7)"],"submitter":["Alberge JB"],"pubmed_abstract":["The International Myeloma Working Group recently fully incorporated <sup>18</sup>F-FDG PET into multiple myeloma (MM) diagnosis and response evaluation. Moreover, a few studies demonstrated the prognostic value of several biomarkers extracted from this imaging at baseline. Before these <sup>18</sup>F-FDG PET biomarkers could be fully endorsed as risk classifiers by the hematologist community, further characterization of underlying molecular aspects was necessary. <b>Methods:</b> Reported prognostic biomarkers (<sup>18</sup>F-FDG avidity, SUV<sub>max</sub>, number of focal lesions, presence of paramedullary disease [PMD] or extramedullary disease) were extracted from <sup>18</sup>F-FDG PET imaging at baseline in a group of 139 patients from CASSIOPET, a companion study of the CASSIOPEIA coh"],"journal":["Journal of nuclear medicine : official publication, Society of Nuclear Medicine"],"pagination":["1008-1013"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9258580"],"repository":["biostudies-literature"],"pubmed_title":["Molecular Signature of <sup>18</sup>F-FDG PET Biomarkers in Newly Diagnosed Multiple Myeloma Patients: A Genome-Wide Transcriptome Analysis from the CASSIOPET Study."],"pmcid":["PMC9258580"],"pubmed_authors":["Touzeau C","Cherel M","Wuilleme S","Corre J","Jamet B","Caillon H","Bailly C","Moreau P","Bene MC","Kampfenkel T","Bodet-Milin C","Carlier T","Alberge JB","Sonneveld P","Avet-Loiseau H","van Duin M","Kraeber-Bodere F","Magrangeas F","Minvielle S"],"additional_accession":[]},"is_claimable":false,"name":"Molecular Signature of <sup>18</sup>F-FDG PET Biomarkers in Newly Diagnosed Multiple Myeloma Patients: A Genome-Wide Transcriptome Analysis from the CASSIOPET Study.","description":"The International Myeloma Working Group recently fully incorporated <sup>18</sup>F-FDG PET into multiple myeloma (MM) diagnosis and response evaluation. Moreover, a few studies demonstrated the prognostic value of several biomarkers extracted from this imaging at baseline. Before these <sup>18</sup>F-FDG PET biomarkers could be fully endorsed as risk classifiers by the hematologist community, further characterization of underlying molecular aspects was necessary. <b>Methods:</b> Reported prognostic biomarkers (<sup>18</sup>F-FDG avidity, SUV<sub>max</sub>, number of focal lesions, presence of paramedullary disease [PMD] or extramedullary disease) were extracted from <sup>18</sup>F-FDG PET imaging at baseline in a group of 139 patients from CASSIOPET, a companion study of the CASSIOPEIA coh","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jul","modification":"2025-04-22T10:12:25.514Z","creation":"2025-04-05T23:28:19.327Z"},"accession":"S-EPMC9258580","cross_references":{"pubmed":["35086897"],"doi":["10.2967/jnumed.121.262884"]}}